598
Views
8
CrossRef citations to date
0
Altmetric
Middle ear

Diagnosis and management of eosinophilic otitis media: a systematic review

ORCID Icon, , , , , & show all
Pages 579-587 | Received 29 Jan 2021, Accepted 03 Mar 2021, Published online: 07 Apr 2021

References

  • Iino Y, Tomioka-Matsutani S, Matsubara A, et al. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx. 2011;38:456–461.
  • Iino Y, Nagamine H, Kakizaki K, et al. Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma. Ann Allergy Asthma Immunol. 2006;97:761–766.
  • Saliba I, Alzahrani M, Weng X, et al. Eosinophilic otitis media diagnosis using flow cytometric immunophenotyping. Acta Otolaryngol. 2018;138:110–115.
  • Esu Y, Iino Y, Masuda M, et al. Proposal of a treatment strategy for eosinophilic otitis media based on middle ear condition. Otol Neurotol. 2018;39:e671–e678.
  • Neff BA, Voss SG, Carlson ML, et al. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b. Laryngoscope. 2017;127:1208–1216.
  • Iino Y, Takahashi E, Ida S, et al. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media. Auris Nasus Larynx. 2019;46:196–203.
  • Iino Y, Hara M, Hasegawa M, et al. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otol Neurotol. 2012;33:1218–1224.
  • Iino Y, Hara M, Hasegawa M, et al. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media. Acta Otolaryngol. 2014;134:366–372.
  • Seo Y, Nonaka M, Yamamura Y, et al. Optimal control of asthma improved eosinophilic otitis media. Asia Pac Allergy. 2018;8:e5
  • Chow K, Cosetti MK. Use of IL-5 inhibitor benralizumab as a novel therapy for eosinophilic otitis media: clinical capsule and review of literature. Otol Neurotol. 2020;41:e238–e240.
  • Fukuda A, Morita S, Nakamaru Y, et al. Differentiation between eosinophilic otitis media and otitis media associated with eosinophilic granulomatosis with polyangiitis. Otol Neurotol. 2019;40:e796–e802.
  • Suzaki I, Kimura Y, Tanaka A, et al. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab. Auris Nasus Larynx. 2019;46:141–146.
  • Han YE, Kang YS, Cho Y, et al. Eosinophilic otitis media treated with anti-IgE monoclonal antibodies and a bone conduction implant. J Int Adv Otol. 2018;14:144–147.
  • de Jong MA, Smithuis LO, Stokroos RJ. [Eosinophilic otitis media]. Ned Tijdschr Geneeskd. 2014;158:A8044.
  • Childers AL, Gruen J, Sayeed S, et al. Eosinophilic otitis media. Otol Neurotol. 2014;35:e206–e207.
  • Turkmen MT, Yagiz R. A case of intractable otitis media: eosinophilic otitis media. Balkan Med J. 2014;31:268–269.
  • Tanaka Y, Nonaka M, Yamamura Y, et al. Improvement of eosinophilic otitis media by optimized asthma treatment. Allergy Asthma Immunol Res. 2013;5:175–178.
  • Chung WJ, Lee JH, Lim HK, et al. Eosinophilic otitis media: CT and MRI findings and literature review. Korean J Radiol. 2012;13:363–367.
  • Kojima H, Sakurai Y, Rikitake M, Moriyama H et al. Cochlear implantation in patients with chronic otitis media. Auris Nasus Larynx. 2010;37:415–421.
  • Iwasaki S, Nagura M, Mizuta K. Cochlear implantation in a patient with eosinophilic otitis media. Eur Arch Otorhinolaryngol. 2006;263:365–369.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.